Roles of apoptosis and cellular senescence in cancer and aging

Current Drug Targets

Volumn 17, Issue 4, 2016, Pages 405-415

  Cerella, Claudia ^a   Grandjenette, Cindy ^a   Dicato, Mario ^a   Diederich, Marc ^b  

^a LABORATOIRE DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE DU CANCER   (Luxembourg)

^b Seoul National University   (South Korea)

Author keywords

Aging; Apoptosis; Cancer; Cellular senescence; Stress; Therapy

Indexed keywords

CASPASE 3; CASPASE 7; CASPASE 8; CASPASE 9; CYCLOOXYGENASE 2; FAS LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN BCL 2; PROTEIN P16; PROTEIN P53; STAT3 PROTEIN; ANTINEOPLASTIC AGENT;

AGING; APOPTOSIS; ARTICLE; CANCER PREVENTION; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; EMBRYO DEVELOPMENT; GENE EXPRESSION; HUMAN; INFLAMMATION; MITOCHONDRIAL MEMBRANE POTENTIAL; NEOPLASM; NONHUMAN; PROTEIN PROTEIN INTERACTION; SENESCENCE; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; CELL AGING; DRUG EFFECTS; METABOLISM; NEOPLASMS; TUMOR SUPPRESSOR GENE;

AGING; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL AGING; GENES, TUMOR SUPPRESSOR; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84960172644     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450116666150202155915     Document Type: Article

References (101)

1. Roninson IB, Broude EV, Chang BD. If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat 2001; 4: 303-13.
2. Prieur A, Peeper DS. Cellular senescence in vivo: a barrier to tumorigenesis. Curr Opin Cell Biol 2008; 20: 150-5.
3. Delbridge AR, Valente LJ, Strasser A. The role of the apoptotic machinery in tumor suppression. Cold Spring Harb Perspect Biol 2012; 4(11) pii: 9008789.
4. Campisi J. Aging, tumor suppression and cancer: high wire-act! Mech Ageing Dev. 2005; 126: 51-8.
5. van Heemst D, den Reijer PM, Westendorp RG. Ageing or cancer: a review on the role of caretakers and gatekeepers. Eur J Cancer 2007; 43: 2144-52.
6. Collado M, Serrano M. The power and the promise of oncogeneinduced senescence markers. Nat Rev Cancer 2006; 6: 472-6.
7. Warner HR. Aging and regulation of apoptosis. Curr Top Cell Regul 1997; 35: 107-21.
8. Salminen A, Ojala J, Kaarniranta K. Apoptosis and aging: increased resistance to apoptosis enhances the aging process. Cell Mol Life Sci 2011; 68: 1021-31.
9. Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 2005; 120: 513-22.
10. Collado M, Blasco MA, Serrano M. Cellular senescence in cancer and aging. Cell 2007; 130: 223-33.
11. Schmitt CA. Cellular senescence and cancer treatment. Biochim Biophys Acta 2007; 1775: 5-20.
12. de Bruin EC, Medema JP. Apoptosis and non-apoptotic deaths in cancer development and treatment response. Cancer Treat Rev 2008; 34: 737-49.
13. Collado M, Serrano M. Senescence in tumours: evidence from mice and humans. Nat Rev Cancer 2010; 10: 51-7.
14. Schmitt CA. Senescence, apoptosis and therapy--cutting the lifelines of cancer. Nat Rev Cancer 2003; 3: 286-95.
15. Lock RB, Stribinskiene L. Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival. Cancer Res 1996; 56: 4006-12.
16. Munoz-Espin D, Canamero M, Maraver A, et al. Programmed cell senescence during mammalian embryonic development. Cell 2013; 155: 1104-18.
17. Storer M, Mas A, Robert-Moreno A, et al. Senescence is a developmental mechanism that contributes to embryonic growth and patterning. Cell 2013; 155: 1119-30.
18. Banito A, Lowe SW. A new development in senescence. Cell 2013; 155: 977-8.
19. Gorgoulis VG, Halazonetis TD. Oncogene-induced senescence: the bright and dark side of the response. Curr Opin Cell Biol 2010; 22: 816-27.
20. Nardella C, Clohessy JG, Alimonti A, Pandolfi PP. Pro-senescence therapy for cancer treatment. Nat Rev Cancer 2011; 11: 503-11.
21. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26: 239-57.
22. Cerella C, Teiten MH, Radogna F, Dicato M, Diederich M. From nature to bedside: Pro-survival and cell death mechanisms as therapeutic targets in cancer treatment. Biotechnol Adv 2014; 32: 1111-22.
23. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646-74.
24. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene 2004; 23: 2825-37.
25. Vanden Berghe T, Linkermann A, Jouan-Lanhouet S, Walczak H, Vandenabeele P. Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nat Rev Mol Cell Biol 2014; 15: 135-47.
26. Tait SW, Green DR. Caspase-independent cell death: leaving the set without the final cut. Oncogene 2008; 27: 6452-61.
27. Colell A, Green DR, Ricci JE. Novel roles for GAPDH in cell death and carcinogenesis. Cell Death Differ 2009; 16: 1573-81.
28. Placzek WJ, Wei J, Kitada S, Zhai D, Reed JC, Pellecchia M. A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy. Cell Death Dis 2010; 1: e40.
29. Willimott S, Wagner SD. Post-transcriptional and post-translational regulation of Bcl2. Biochem Soc Trans 2010; 38: 1571-5.
30. Maser RS, Antoku K, Scully WJ, Jr., Cho RL, Johnson DE. Analysis of the role of conserved cysteine residues in the bcl-2 oncoprotein. Biochem Biophys Res Commun 2000; 277: 171-8.
31. D'Alessio M, De Nicola M, Coppola S, et al. Oxidative Bax dimerization promotes its translocation to mitochondria independently of apoptosis. FASEB J 2005; 19: 1504-6.
32. Danial NN, Gimenez-Cassina A, Tondera D. Homeostatic functions of BCL-2 proteins beyond apoptosis. Adv Exp Med Biol 2010; 687: 1-32.
33. Quinn BA, Dash R, Azab B, et al. Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs 2011; 20: 1397-411.
34. Meynet O, Zunino B, Happo L, et al. Caloric restriction modulates Mcl-1 expression and sensitizes lymphomas to BH3 mimetic in mice. Blood 2013; 122: 2402-11.
35. Billard C. BH3 mimetics: status of the field and new developments. Mol Cancer Ther 2013; 12: 1691-700.
36. Khaw SL, Merino D, Anderson MA, et al. Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. Leukemia 2014; 28: 1207-15.
37. Faber AC, Coffee EM, Costa C, et al. mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. Cancer Discov 2014; 4: 42-52.
38. Delhalle S, Blasius R, Dicato M, Diederich M. A beginner's guide to NF-kappaB signaling pathways. Ann N Y Acad Sci 2004; 1030: 1-13.
39. Erstad DJ, Cusack JC, Jr.. Targeting the NF-kappaB pathway in cancer therapy. Surg Oncol Clin N Am 2013; 22: 705-46.
40. Sobolewski C, Cerella C, Dicato M, Diederich M. Cox-2 inhibitors induce early c-Myc downregulation and lead to expression of differentiation markers in leukemia cells. Cell Cycle 2011; 10: 2978-93.
41. Liu F, Bardhan K, Yang D, et al. NF-kappaB directly regulates Fas transcription to modulate Fas-mediated apoptosis and tumor suppression. J Biol Chem 2012; 287: 25530-40.
42. Folmer F, Jaspars M, Dicato M, Diederich M. Marine natural products as targeted modulators of the transcription factor NFkappaB. Biochem Pharmacol 2008; 75: 603-17.
43. Juncker T, Cerella C, Teiten MH, et al. UNBS1450, a steroid cardiac glycoside inducing apoptotic cell death in human leukemia cells. Biochem Pharmacol 2011; 81: 13-23.
44. Orlikova B, Schumacher M, Juncker T, et al. Styryl-lactone goniothalamin inhibits TNF-alpha-induced NF-kappaB activation. Food Chem Toxicol 2013; 59: 572-8.
45. Cerella C, Sobolewski C, Dicato M, Diederich M. Targeting COX-2 expression by natural compounds: a promising alternative strategy to synthetic COX-2 inhibitors for cancer chemoprevention and therapy. Biochem Pharmacol 2010; 80: 1801-15.
46. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128: 683-92.
47. Schnekenburger M, Dicato M, Diederich M. Epigenetic modulators from "The Big Blue": a treasure to fight against cancer. Cancer Lett 2014; 351: 182-97.
48. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell 2013; 153: 1194-217.
49. Wang J, Lu X, Klein CA, Rudolph KL. Quiescent hematopoietic stem cells with short telomeres accumulate genomic damage but are blocked from hematopoietic activation by senescence and apoptosis. Blood 2014; 124: 3237-40.
50. Cao JN, Gollapudi S, Sharman EH, Jia Z, Gupta S. Age-related alterations of gene expression patterns in human CD8+ T cells. Aging Cell 2010; 9: 19-31.
51. Haigis MC, Yankner BA. The aging stress response. Mol Cell 2010; 40: 333-44.
52. Yee C, Yang W, Hekimi S. The intrinsic apoptosis pathway mediates the pro-longevity response to mitochondrial ROS in C. elegans. Cell 2014; 157: 897-909.
53. Nakayama M, Ishibashi T, Ishikawa HO, et al. A gain-of-function screen to identify genes that reduce lifespan in the adult of Drosophila melanogaster. BMC Genet 2014; 15: 46.
54. Campisi J, Andersen JK, Kapahi P, Melov S. Cellular senescence: a link between cancer and age-related degenerative disease? Semin Cancer Biol 2011; 21: 354-9.
55. Kavathia N, Jain A, Walston J, Beamer BA, Fedarko NS. Serum markers of apoptosis decrease with age and cancer stage. Aging (Albany NY) 2009; 1: 652-63.
56. Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res 1961; 25: 585-621.
57. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003; 426: 194-8.
58. Decottignies A, d'Adda di Fagagna F. Epigenetic alterations associated with cellular senescence: a barrier against tumorigenesis or a red carpet for cancer? Semin Cancer Biol 2011; 21: 360-6.
59. Zane L, Sharma V, Misteli T. Common features of chromatin in aging and cancer: cause or coincidence? Trends Cell Biol 2014; 24: 686-94.
60. Bieging KT, Mello SS, Attardi LD. Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer 2014; 14: 359-70.
61. Sun P, Yoshizuka N, New L, et al. PRAK is essential for rasinduced senescence and tumor suppression. Cell 2007; 128: 295-308.
62. Dotto GP. p21(WAF1/Cip1): more than a break to the cell cycle? Biochim Biophys Acta 2000; 1471: M43-56.
63. Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 1999; 397: 164-8.
64. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA. Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996; 85: 27-37.
65. Brown JP, Wei W, Sedivy JM. Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. Science 1997; 277: 831-4.
66. Beausejour CM, Krtolica A, Galimi F, et al. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J 2003; 22: 4212-22.
67. Sage J, Miller AL, Perez-Mancera PA, Wysocki JM, Jacks T. Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature 2003; 424: 223-8.
68. Larsson LG. Oncogene-and tumor suppressor gene-mediated suppression of cellular senescence. Semin Cancer Biol 2011; 21: 367-76.
69. Chen Z, Trotman LC, Shaffer D, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005; 436: 725-30.
70. Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev 2012; 26: 1268-86.
71. Gire V, Wynford-Thomas D. Reinitiation of DNA synthesis and cell division in senescent human fibroblasts by microinjection of anti-p53 antibodies. Mol Cell Biol 1998; 18: 1611-21.
72. Dirac AM, Bernards R. Reversal of senescence in mouse fibroblasts through lentiviral suppression of p53. J Biol Chem 2003; 278: 11731-4.
73. McDuff FK, Turner SD. Jailbreak: oncogene-induced senescence and its evasion. Cell Signal 2011; 23: 6-13.
74. Leidal AM, Pringle ES, McCormick C. Evasion of oncogeneinduced senescence by gammaherpesviruses. Curr Opin Virol 2012; 2: 748-54.
75. Leidal AM, Lee PW, McCormick C. Viral subversion of autophagy impairs oncogene-induced senescence. Autophagy 2012; 8: 1138-40.
76. Felsher DW. Tumor dormancy and oncogene addiction. APMIS 2008; 116: 629-37.
77. Bellovin DI, Das B, Felsher DW. Tumor dormancy, oncogene addiction, cellular senescence, and self-renewal programs. Adv Exp Med Biol 2013; 734: 91-107.
78. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007; 7: 834-46.
79. Di Mitri D, Toso A, Chen JJ, et al. Tumour-infiltrating Gr-1 myeloid cells antagonize senescence in cancer. Nature 2014; 515: 134-7.
80. Toso A, Revandkar A, Di Mitri D, et al. Enhancing chemotherapy efficacy in pten-deficient prostate tumors by activating the senescence-associated antitumor immunity. Cell Rep 2014; 9: 75-89.
81. Wang DJ, Ratnam NM, Byrd JC, Guttridge DC. NF-kappaB Functions in Tumor Initiation by Suppressing the Surveillance of Both Innate and Adaptive Immune Cells. Cell Rep 2014; 9: 90-103.
82. Gewirtz DA, Holt SE, Elmore LW. Accelerated senescence: an emerging role in tumor cell response to chemotherapy and radiation. Biochem Pharmacol 2008; 76: 947-57.
83. Elmore LW, Rehder CW, Di X, et al. Adriamycin-induced senescence in breast tumor cells involves functional p53 and telomere dysfunction. J Biol Chem 2002; 277: 35509-15.
84. Bunz F, Hwang PM, Torrance C, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999; 104: 263-9.
85. Rubio LM, Rangaraj P, Homer MJ, Roberts GP, Ludden PW. Cloning and mutational analysis of the gamma gene from Azotobacter vinelandii defines a new family of proteins capable of metallocluster binding and protein stabilization. J Biol Chem 2002; 277: 14299-305.
86. Goytisolo FA, Samper E, Martin-Caballero J, et al. Short telomeres result in organismal hypersensitivity to ionizing radiation in mammals. J Exp Med 2000; 192: 1625-36.
87. Atkinson SP, Keith WN. Epigenetic control of cellular senescence in disease: opportunities for therapeutic intervention. Expert Rev Mol Med 2007; 9: 1-26.
88. Schnekenburger M, Grandjenette C, Ghelfi J, et al. Sustained exposure to the DNA demethylating agent, 2'-deoxy-5-azacytidine, leads to apoptotic cell death in chronic myeloid leukemia by promoting differentiation, senescence, and autophagy. Biochem Pharmacol 2011; 81: 364-78.
89. Grandjenette C, Schnekenburger M, Karius T, et al. 5-aza-2'-deoxycytidine-mediated c-myc Down-regulation triggers telomeredependent senescence by regulating human telomerase reverse transcriptase in chronic myeloid leukemia. Neoplasia 2014; 16: 511-28.
90. Tyner SD, Venkatachalam S, Choi J, et al. p53 mutant mice that display early ageing-associated phenotypes. Nature 2002; 415: 45-53.
91. Maier B, Gluba W, Bernier B, et al. Modulation of mammalian life span by the short isoform of p53. Genes Dev 2004; 18: 306-19.
92. Krishnamurthy J, Torrice C, Ramsey MR, et al. Ink4a/Arf expression is a biomarker of aging. J Clin Invest 2004; 114: 1299-307.
93. Chin L, Artandi SE, Shen Q, et al. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 1999; 97: 527-38.
94. Anchelin M, Alcaraz-Perez F, Martinez CM, Bernabe-Garcia M, Mulero V, Cayuela ML. Premature aging in telomerase-deficient zebrafish. Dis Model Mech 2013; 6: 1101-12.
95. Choudhury AR, Ju Z, Djojosubroto MW, et al. Cdkn1a deletion improves stem cell function and lifespan of mice with dysfunctional telomeres without accelerating cancer formation. Nat Genet 2007; 39: 99-105.
96. Baker DJ, Weaver RL, van Deursen JM. p21 both attenuates and drives senescence and aging in BubR1 progeroid mice. Cell Rep 2013; 3: 1164-74.
97. Sorrentino JA, Krishnamurthy J, Tilley S, Alb JG, Jr., Burd CE, Sharpless NE. p16INK4a reporter mice reveal age-promoting effects of environmental toxicants. J Clin Invest 2014; 124: 169-73.
98. Krishnamurthy J, Ramsey MR, Ligon KL, et al. p16INK4a induces an age-dependent decline in islet regenerative potential. Nature 2006; 443: 453-7.
99. Molofsky AV, Slutsky SG, Joseph NM, et al. Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing. Nature 2006; 443: 448-52.
100. Valk-Lingbeek ME, Bruggeman SW, van Lohuizen M. Stem cells and cancer; the polycomb connection. Cell 2004; 118: 409-18.
101. Childs BG, Baker DJ, Kirkland JL, Campisi J, van Deursen JM. Senescence and apoptosis: dueling or complementary cell fates? EMBO Rep 2014; 15: 1139-53.